NEW YORK, July 26, 2026, 4:00 p.m. EDT — U.S. markets have closed.
- The share price closed at $34.79 on Friday, marking a 6.2% loss over the week.
- The average estimate for the second-quarter loss increased by 24% over the past three months to $1.23 per share.
- A straight-line preliminary estimate calculates March liquidity at 5.3 quarters of first-quarter operating cash burn.
Viking heads into earnings week as its shares face downward pressure. The stock dropped 6.2% last week, with a 1.7% decrease on Friday.
The key issue is cash.
Viking will announce its second-quarter results following the close on Wednesday. The company’s conference call is scheduled for 4:30 p.m. EDT.
Analysts now expect a per-share loss of $1.23, marking a 24% increase compared to three months earlier. The projected annual loss has grown by 18% to $4.75.
The market value on Friday stood at $4.02 billion, while liquidity in March was $603 million. This resulted in a surplus of approximately $3.42 billion over liquidity, not counting other assets and liabilities.
Rising expenditures account for the changes in estimates. Research expenses jumped 263%, reaching $150.2 million in the first quarter. Operating cash outflows increased sharply, more than doubling to $114.0 million.
Friday’s market prices, analysts’ consensus estimates and company disclosures reflect the change.
| Investor measure | Latest | Earlier comparison | Change |
|---|---|---|---|
| Share price | $34.79 | $37.08 on July 17 | -6.2% |
| Q2 loss estimate | $1.23 a share | $0.99 three months ago | 24% greater |
| 2026 loss estimate | $4.75 a share | $4.01 three months ago | 18% greater |
| Q1 research spending | $150.2 million | $41.4 million year earlier | +263% |
| Q1 operating cash use | $114.0 million | $52.3 million year earlier | +118% |
A basic straight-line estimate suggests that March liquidity covers 5.3 quarters of first-quarter cash burn. This is not company guidance. Viking stated its cash should be sufficient until at least June 30, 2027.
The timing now coincides with significant clinical expenditures. Data on maintenance dosing are anticipated this quarter. An oral Phase 3 trial is scheduled for the fourth quarter.
Viking is strengthening its commercial capabilities. Last week, Chief Executive Brian Lian stated the company is “preparing for VK2735’s potential launch” while announcing the addition of a new director. Viking Therapeutics InvestorRoom
The level of competition increased simultaneously. Eli Lilly NYSE:LLY showed a 22.6% weight loss in one Phase 3 trial for retatrutide, while a separate study in diabetes patients recorded a 20.8% reduction.
Lilly intends to submit a U.S. application in the first quarter of 2027. Executive Vice President Kenneth Custer described retatrutide as “an important future tool” for treating cardiometabolic conditions. Reuters
The market divided sharply on Friday. Lilly advanced 0.9%, Novo Nordisk NYSE:NVO climbed 1.3%, while Viking fell 1.7%.
Analyst price targets highlight the continued binary outlook. The lowest estimate is $34, almost matching Friday’s closing price. The consensus average is $94.29.
Wednesday’s update is expected to address three key points. Market participants are set to focus on cash levels, research expenditure, and any modifications to runway projections. The schedule for third-quarter data will also come under scrutiny.
Risks are still elevated. Viking does not generate revenue, while advanced trials may be delayed or unsuccessful. Accelerated expenditures could mean earlier dilution. Data from Lilly could also set a higher efficacy standard.
At present, Viking’s balance sheet could influence the shares ahead of its trial results.
Related articles: NYSE:LLY
